Vertex Names New CEO

On April 1st, Reshma Kewalramani assumed the positon of CEO at NEC member Vertex. Dr. Kewalramani was announced as the new CEO—and the company’s first female CEO–last July.

Dr. Kewalramani suceeds Dr. Jeffrey Leiden, who led Vertex for seven years and helped it to become one of Massachusetts’ most competitive and successful biotech companies. He was honored by the Council as a New Englander of the Year in 2018. Dr. Kewalramani joined Vertex in 2018 and has shown expertise in knowing which drug candidates are worth investing in and which to stop researching. Vertex is expected to work on drug candidates for alpha-1 antitrypsin deficiency, which can cause disease in the liver and lungs. Dr. Kewalramani discussed five possible treatments at a J.P.Morgan conference in January.

“These are very big ideas that are really transformative for each field. They’re stretching the boundaries of science. It’s really exciting,” she said. “It’s risky, but I think it’s a risk they can take.”

The New England Council congratulates Dr. Kewalramani and wishes her much success in her new role. Boston Business Journal reports.

img_side
mask_sidebar
Recently from the Blog

Media Panel Discusses Biden’s First 100 Days

05/3/2021 | Read Post

Second “Investing in Infrastructure” Program to Focus on Energy

04/29/2021 | Read Post

In the News

NEC Board Elects Three New Directors

04/27/2021 | Read Press Release

NEC Endorses Cannabis Banking Legislation

04/1/2021 | Read Press Release